5 active not recruiting, 4 completed, 1 recruiting. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Active not recruiting 5, Completed 4, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Refractory Primary Central Nervous System Neoplasm: new trials by email Literature Review of Refractory Primary Central Nervous System Neoplasm trials Research Report on Refractory Primary Central Nervous System Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-11-16 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-11-13 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-11-13 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2017-10-30 | 2025-02-05 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-11-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-11-13 |
Central Nervous System Neoplasms (10) · Ependymoma (8) · Glioma (8) · Hepatoblastoma (8) · Lymphoma, Non-Hodgkin (8) · Neuroblastoma (8) · Wilms Tumor (8) · Histiocytosis, Langerhans-Cell (7) · Medulloblastoma (7) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Osteosarcoma (7) · Rhabdoid Tumor (7) · Rhabdomyosarcoma (7) · Sarcoma (7) · Sarcoma, Ewing (4)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Neoplasms, Nerve Tissue (10) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neuroectodermal Tumors (10) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Neuroepithelial (9) · Neuroectodermal Tumors, Primitive (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genetic Diseases, Inborn (8)
Magnetic Resonance Spectroscopy (5) · Phantoms, Imaging (5) · Specimen Handling (5) · X-Rays (5) · Biopsy (4) · Nuclear Medicine Department, Hospital (4) · LY3023414 (2) · Vemurafenib (2) · ensartinib (2) · erdafitinib (2) · larotrectinib (2) · olaparib (2) · AZD 6244 (1) · cabozantinib (1) · ivosidenib (1)
National Cancer Institute (NCI) (9) · Nationwide Children's Hospital (1)
United States (10) · Puerto Rico (8) · Australia (2) · Canada (2)
AeRang Kim (1) · Alice Lee (1) · Carl E Allen (1) · Donald W Parsons (1) · Julia Glade-Bender (1) · Katherine A Janeway (1) · Margot Lazow, MD (1) · Meredith S Irwin (1) · Srivandana Akshintala (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 33591402, PMID 34486544, PMID 35353553, PMID 35363510, PMID 38815151, PMID 38873934, PMID 41166674, PMID 42686334
U10CA180886 (9), UM1CA081457 (1)